梅尼埃病生活质量量表的开发与初步验证:MenQOL
本研究通过专家输入、患者焦点小组和问卷反应分析开发了24条目的梅尼埃病生活质量量表(MenQOL),并在50例梅尼埃病患者与60例其他原因耳鸣、眩晕或听力下降患者中验证。探索性因子分析显示单领域,Cronbach's α=0.914;梅尼埃病患者MenQOL均分显著差于对照组(52.5±15.8 vs. 43.2±12.6;p=0.0051)。
要点
- MenQOL为24条目单领域量表,Cronbach's α=0.914提示内部一致性高。
- 梅尼埃病患者MenQOL均分52.5±15.8,显著差于对照组43.2±12.6(p=0.0051)。
- MenQOL总分与SF-36v2躯体及心理综合分呈显著负相关,显示可接受的同时效度。
核心结论
- 初步开发了MenQOL,一种简单、有效的患者报告结局量表,在进一步研究的前提下,或可用于评估梅尼埃病患者治疗对疾病特异性生活质量的影响。
研究设计与样本
- 通过专家输入、患者焦点小组和草拟问卷反应分析的序贯过程开发24条目MenQOL量表。
- 在一家三级学术中心纳入50例梅尼埃病患者和60例其他原因耳鸣、眩晕或听力下降的对照患者,施测MenQOL与SF-36v2。
- 采用探索性因子分析、Cronbach's α、组间总分比较及MenQOL与SF-36v2的回归分析评估量表结构、内部一致性、表面效度和外部效度。
主要发现
- 探索性因子分析显示MenQOL为单领域。
- Cronbach's α=0.914表明量表整体内部一致性高。
- 梅尼埃病患者MenQOL均分52.5±15.8,显著差于对照组43.2±12.6(p=0.0051),提示结构效度良好。
- 双变量线性回归中,MenQOL总分与SF-36v2躯体综合分(斜率=-0.94,p<0.0001)及心理综合分(斜率=-1.16,p<0.0001)呈显著负相关,显示可接受的同时效度。
临床怎么用
- 作者认为MenQOL作为一种简单、有效的患者报告结局量表,在进一步研究的前提下,或可用于评估梅尼埃病患者治疗对疾病特异性生活质量的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To design and validate a disease-specific quality of life instrument for Meniere's disease. METHODS: We used a sequential process of expert input, patient focus groups, and analyses of responses to draft questionnaires to create a 24-item Meniere's disease quality of life (MenQOL) instrument. The MenQOL and the SF-36v2 were administered to a cohort of 50 patients with Meniere's disease and 60 comparison patients with tinnitus, vertigo, or hearing loss from other causes identified at a tertiary academic center. We performed exploratory factor analysis, Cronbach's α, between group comparisons of total MenQOL scores, and regression analyses between the MenQOL and SF-36v2 to evaluate the instrument's factor structure, internal consistency, face validity, and external validity. Segregation of the instrument into domains was assessed by exploratory factor analysis. RESULTS: Exploratory factor analysis revealed that the MenQOL has a single domain. Cronbach's α = 0.914 indicated high internal consistency for the instrument as a whole. Mean MenQOL scores showing significantly worse quality of life among patients with Meniere's disease than comparison participants (52.5 ± 15.8 vs. 43.2 ± 12.6; p = 0.0051), indicating good construct validity. Significant inverse relationships in bivariate linear regressions between total MenQOL scores and SF-36v2 physical (slope = -0.94, p < 0.0001) and mental (slope = -1.16, p < 0.0001) composite scores showed acceptable concurrent validity. CONCLUSIONS: We have described the initial development of the MenQOL, a simple, valid patient-reported outcome measure that, subject to further study, may be used to assess the effects of treatment on disease-specific quality of life in patients with Meniere's disease. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:4351-4357, 2024.
引用
- Quimby AE, Brant JA, Staab JP, et al. Development and Initial Validation of a Meniere's Disease Quality of Life Instrument: The MenQOL. Laryngoscope. 2024. PMID: 38689521. doi:10.1002/lary.31478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。